Healthcare
Live Price
Offline$9.10
+0.06% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CTI BioPharma Corp. (CTIC) is a Healthcare stock with a market cap of $1.20B. The stock last traded around $9.10. Baseline metrics include revenue growth of 0.0%, EPS growth of +28.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +28.8%, free cash flow -25.1% with operating margin -147.9% and ROIC -84.2%. Valuation already assumes a fairly strong business story at price/sales 22.2. Stock Foundry combines CTIC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CTIC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CTIC Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CTIC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$26.3M
+685.9% YoY
FY Net Income
-$29.3M
+30.7% YoY
Free Cash Flow
-$39.9M
-43.3% YoY
Revenue Growth
+0.0%
EPS Growth
+28.8%
Gross Margin
93.5%
Net Margin
-168.8%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 54M | 0 | 0 | 3M | 26M |
| Gross Profit | 50M | -161K | -4M | 3M | 25M |
| Operating Income | -80M | -95M | -48M | -41M | -33M |
| EBITDA | -80M | -95M | -51M | -37M | -33M |
| Net Income | -91M | -100M | -53M | -42M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30M | 65M | 40M | 31M | 36M |
| Total Assets | 126M | 72M | 58M | 46M | 90M |
| Total Liabilities | 144M | 69M | 18M | 28M | 37M |
| Shareholder Equity | -18M | 4M | 40M | 18M | 59M |
| Total Debt | 50M | 51M | 5M | 12M | 14M |
| Net Debt | 20M | -15M | -35M | -19M | -22M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
40M
-43.1% YoY
Capital Expenditures
33K
Free Cash Flow
40M
-43.3% YoY
Key ratios
Gross Margin
93.5%
Operating Margin
-147.9%
Net Margin
-168.8%
ROE
1318.5%
Debt / Equity
-2.84x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.